Aurora Investment Counsel Has $2.65 Million Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Aurora Investment Counsel increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,698 shares of the company’s stock after purchasing an additional 232 shares during the quarter. Amphastar Pharmaceuticals makes up about 1.4% of Aurora Investment Counsel’s portfolio, making the stock its 10th largest holding. Aurora Investment Counsel owned about 0.11% of Amphastar Pharmaceuticals worth $2,654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in AMPH. GAMMA Investing LLC lifted its stake in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares during the last quarter. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Blue Trust Inc. boosted its position in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after buying an additional 309 shares during the period. Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The trade was a 3.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the completion of the transaction, the director now owns 31,471 shares in the company, valued at approximately $1,535,784.80. The trade was a 13.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,533 shares of company stock valued at $1,571,652 over the last 90 days. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $44.09 on Thursday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company’s fifty day simple moving average is $48.38 and its 200 day simple moving average is $44.42. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 0.89 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Finally, Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.